ACSRC seminar series/Translational Oncology Grand Round: How to work together on Granulosa Cell Tumour of the ovary Event as iCalendar

17 May 2013

2 - 3pm

Venue: Clinical Education Centre, Level 5, Auckland City Hospital

Granulosa cell tumours (GCTs) represent a specific subset of malignant ovarian tumours.  Although GCTs are generally thought to have a better prognosis than the more common ovarian epithelial tumours, up to 50% of women will have recurrence of their tumour and ~ 80% of patients with advanced or recurrent tumours will die from their disease Despite the impact of this disease on affected women, remarkably little is known about the molecular changes that give rise to GCTs, and how to predict clinical outcomes. GCTs represent a relatively homogenous, distinct tumour type (in contrast to epithelial ovarian tumours) arising from granulosa cells through a limited set of molecular events which activate specific signalling pathways. The goal of this project is to identify the genes which contribute, through mutation or altered expression, to the pathogenesis of GCT, and to link this to clinical outcomes. We consider that by combining molecular and clinical data, which we can begin to improve the outcomes for women with GCT.


  • Dr Michelle Wilson, Registrar, Medical Oncology, ADHB
  • Dr Peter Fong, Medical Oncologist, Medical Oncology, ADHB
  • Associate Professor Andrew Shelling, Department of Obstetrics & Gynaecology and Associate Dean Research, FMHS, University of Auckland
  • Roseanne Rosario, PhD student, Department of Obstetrics & Gynaecology, FMHS, University of Auckland

Open session - all welcome

For further information please contact Dr Ben Lawrence,